3Karakoc B, Erenus M .Compliance considerations with hormone replacement therapy. Menopause, 1998 , 5(2): 102-106.
4Elliott ME, Meek PD, Kanous NL,et al.Pharmacy-based bone mass measurement to assess osteoporosis risk. Ann Pharmacother, 2002 , 36(4): 571-577.
5Silverman SL, Greenwald M, Klein RA,et al.Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol, 1997 , 89(3): 321-325 .
6Sedlak CA ,Doheny MO, Jones SL. Osteoporosis prevention in young women. Orthop Nurs. 1998, 17(3):53-56.
7Juby AG,Davis P. A prospective evaluation of the awareness, knowledge, risk factors and current treatment of osteoporosis in a cohort of elderly subjects. Osteoporos Int, 2001, 12(8): 617-622 .
8Kasper MJ, Peterson MG, Allegrante JP .The need for comprehensive educational osteoporosis prevention programs for young women: results from a second osteoporosis prevention survey. Arthritis Rheum, 2001 , 45(1): 28-34 .
9Thomas LG, Corwin EJ .The readability of printed education materials regarding hormone replacement therapy. J Am Acad Nurse Pract, 1998 ,10(10): 447-452 .
10Ailinger RL , Harper DC, Lasus HA. Bone up on osteoporosis : Development of the Facts on Osteoporosis Quiz. Orthop Nurs,1998,17(5):66-73.
2SAHANA H,KHAJURIA D K,RAZDAN R,et al.Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis[J].Journal of Biomedical Nanotechnology,2013,9(2):193.
3Bessette L ,Ste-Marie LG ,Jean S ,et al. Recognizing osteoporosis and its consequences in Quebec (ROCQ) : background, rationale, and methods of an anti-fracture patient health-management programme[J]. Contemp Clin Trials, 2008,29 (2) : 194-210.
4Lyell V, Henderson E, Devine M, et al. Assessment and management of fracture risk in patients with Parkinson's disease[J]. Age Ageing,2015, 44(1):34-41.
5Sale JE, Cameron C, Hawker G, et al. Strategies used by an osteoporosis patient group to navigate for bone health care after a fracture[J]. Arch Or- thop Trauma Surg,201g, 134(2) :229-235.
6Lee CE, Leslie WD, Czaykowski P, et al. A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy[J]. Curr Onco1,2011,18(4) :e163-172.
8Fonseca V,Desouza C,Asnani S, et al.Nontraditional Risk Fac- tors for Cardiovascular Disease in Diabetes [J].Endocr Rev, 2014,20(1):153-159.
9Periard D,Monney P,Waeber G.Randomized Contro!led Trial of Peripherally Inserted Central Catheters Vs.Peripheral Catheters for Middle Duration In-Hospital Intravenous Ther- apy[J].Thromb Haemost,2012,6(8):281-286.
10Matsuzaki A,Suminoe A,Koga Y,et al.Long-Term Use of Pe- ripherally Inserted Central Venous Catheters for Cancer Chemotherapy in Children [J].Support Care Cancer,2013,14 (2):154-161.
